Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS: SEPTEMBER ISSUE PUBLISHED
  • SEPTEMBER 2021 Issue has been successfully launched on 1 September 2021.

Abstract

RECOMBINANT HUMAN INTERFERON-BETA: CURRENT PERSPECTIVES

DharamPal, Madaka Surya Teja, A.R. Satvik Iyengar and Abhay H. Pande*

ABSTRACT

Recombinant human interferon-beta (rhIFN-β) is a drug of choice for the treatment of multiple sclerosis and is also a potential candidate for the treatment of several other diseases in humans. However, there are several issues associated with the production of this therapeutic protein. In this review, we have presented the current perspectives on rhIFN-β. In the early part of this review, we have discussed about the characteristics of human IFNs, with a major emphasis on hIFN-β, followed by a brief discussion on the clinical applications of rhIFN-β. The later part of the review elaborates pros and cons of various expression systems used to produce rhIFN-β and various assays used to characterize the properties of recombinantly produced hIFN-β. Understanding the intricacies of the available production and characterization systems for rhIFN-β will have tremendous commercial impact. This may lead to cost effective generation of this therapeutic protein which will benefit both manufacturers and end users (patients).

Keywords: recombinant protein; interferon-?; expression systems, E. coli, inclusion bodies.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More